Phase 3 N=1,047 Expanded Access Program for Maraviroc At Multiple Centers
HIV Infections
Primary: Percentage of Participants With Grade 3 and Grade 4 Adverse Events (AE) — 13.2; 2.4; 6.3; 1.6 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,615 MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1C (A1C) at Week 24 — -1.09; -0.88; -1.21; -1.20 Percentage of glycosylated hemoglobin
Phase 3 N=850 A Study of Omalizumab (Xolair) in Subjects With Moderate to Severe Persistent Asthma (EXTRA)
Asthma
Primary: Rate of Asthma Exacerbations Over the 48 Week Treatment Period — 0.88; 0.66 exacerbation/patient-week
Phase 3 N=92 Safety Study of GSK Biologicals' HPV Vaccine (GSK-580299) in Healthy Female Subjects.
Infections, Papillomavirus
Primary: Number of Subjects Reporting Any Serious Adverse Event (SAE) and SAE(s) With a Causal Relationship to Vaccination as Assessed by the Investigator. — 3; 0 Subjects
Phase 3 N=20 Contrast-enhanced MRI in Children 2 Months to <2 Years
Magnetic Resonance Imaging
Primary: Number of Participants With Diagnostic Adequacy - Open-label Clinical Investigators (Per Protocol Set) — 1; 0; 2; 3 Participants
Phase 3 N=455 Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study
Neoplasms, Breast
Primary: Number of Participants With Pathological Complete Response (pCR) at the Time of Surgery — 38; 44; 78 participants — p=0.3416
Phase 3 N=59,721 Impact of Maternal Vitamin A or Beta-Carotene Supplementation on Maternal and Infant Mortality in Bangladesh
Vitamin A Deficiency · Maternal Mortality · Infant Mortality
Primary: All-cause, Pregnancy-related Mortality — 41; 47; 50 Participants — p=0.05
Phase 3 N=493 The Effect Of Dose Titration And Dose Tapering On The Tolerability Of DVS SR In Women With Vasomotor Symptoms
Vasomotor Symptoms
Primary: Number of Participants With Nausea During the First 2 Weeks of Treatment — 24; 31; 28; 43 Participants — p=0.024
Phase 3 N=110 Effects of Anorexia Nervosa on Bone Mass in Adolescents
Anorexia Nervosa
Primary: Percent Change in Spine Bone Density Over the Study Duration (18 Months) — 2.6; 0.3 Percent change — p=<0.05
Phase 3 N=1,522 Second Extension Study to Evaluate Safety and Tolerability of Influenza Vaccines in Adults and Elderly, and to Evaluate Immunogenicity and Concomitant Vaccination With Pneumococcal Vaccine in a Subgroup
Influenza
Primary: Number of Randomized Participants Reporting Local and Systemic Reactions. — 52; 37; 24; 19 Subjects
Phase 3 N=302 Clinical Evaluation of Ropinirole Prolonged Release/Extended Release (PR/XR) Tablet for Adjunctive Therapy to L-dopa in Subjects With Advanced Parkinson's Disease
Parkinson Disease
Primary: Mean Change From Week 0 (Baseline) in the Japanese Unified Parkinson's Disease Rating Scale (UPDRS) Part III Total Score at the Final Assessment Point (FAP) (up to Week…
Phase 3 N=629 Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: Number of Participants With Adverse Events. — 395; 189 participants
Phase 3 N=488 Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
Schizophrenia
Primary: Primary Efficacy Endpoint: Mean Change in Total PANSS Score From Baseline to the End of the Double Blind Phase — -22.2; -26.5; -27.8; -10.3 scores on a scale — p=<0.05
Phase 3 N=343 Safety and Efficacy of Gadobutrol 1.0 Molar ( Gadavist ) in Patients for Central Nervous System (CNS) Imaging
Central Nervous System Diseases
Primary: Scores for Three Visualization Parameters (Contrast Enhancement, Border Delineation and Internal Morphology) for Combined Unenhanced/Gadobutrol-enhanced Magnetic…
Phase 3 N=93 Study To Evaluate 24 Hour Blood Sugar Control (24-hour Mean Weighted Glucose) In Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared To Subjects Taking Metformin XR 1500 mg Up-titrated To Metformin XR 2000 mg
Type 2 Diabetes
Primary: Change From Baseline in 24-Hour Mean Weighted Glucose (MWG) at Week 4 — 191.3; 192.0; 173.2; 184.2 mg/dL — p=0.1278